These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 19903091)

  • 1. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
    Haidar A; Jønler M; Folkmar TB; Lund L
    Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
    Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T; Cheng A; Stein B; Goss A
    J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
    Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.
    Gebara SN; Moubayed H
    Am J Health Syst Pharm; 2009 Sep; 66(17):1541-7. PubMed ID: 19710437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case.
    Shirota T; Nakamura A; Matsui Y; Hatori M; Nakamura M; Shintani S
    Clin Oral Implants Res; 2009 Dec; 20(12):1402-8. PubMed ID: 19793318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
    Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E
    Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.